- 该列表港股报价延时15分钟
- 1.77-10.08%×
- 0.0009900.00%×
1.77
-0.20-10.08%
Mar 14 4:00 PM EDT
- 今开:1.93
- 最高价:1.96
- 52周最高价:3.58
- 成交量:59202
- 昨收:1.97
- 最低价:1.75
- 52周最低价:1.64
- 市值:0.78亿
- 市盈率:亏损
- 每股收益:-0.72
- 每股派息:--
- 总股本:4431万
- 天演药业盘中异动 下午盘股价大跌5.03%报1.89美元5天前
- 天演药业盘中异动 早盘大幅拉升5.19%报3.65美元24-02-23
- 全球最权威创新药大会之一将召开，多家A股公司将亮相23-05-17
- 天演药业公布2022年上半年财务业绩及公司进展22-08-31
- 天演药业宣布总价值至多1000万美元的股票回购计划22-06-30
- BRIEF-Adagene Announces Publication At Asco Of Interim Monotherapy Dose Escalati...22-05-27
- 天演药业宣布将于五月至六月期间出席多个投资者会议22-05-12
- BRIEF-Adagene Inc Files For Mixed Shelf Of Up To $200 Mln22-04-27
- 天演药业公布2021年全年财务业绩及公司进展22-03-31
- BRIEF-Adagene Reports Full Year 2021 Financial Results22-03-31
- Adagene Shares Pop After FDA Clears Phase 1b/2 Trial For ADG126/Keytruda Combo T...22-03-16
- Adagene, Merck gets FDA clearance to advance ADG126/Keytruda combo in solid tumo...22-03-16
- 生物药企突围出海：从对外授权产品到授权技术22-03-04
- 天演药业与赛诺菲合作开发抗体药物 交易潜值25亿美元22-03-04
- 天演药业与赛诺菲牵手抗体药开发合作，最高超25亿美元22-03-03
- BRIEF-Adagene Announces Safebody Multi-Target Collaboration With Sanofi22-03-02
- 天演药业与赛诺菲达成潜值25亿美元合作，开发新一代掩蔽抗体候选药物22-03-02
- Sanofi Taps Adagene's 'Masking' Tech In Over $2.5B Immuno-Oncology Pact22-03-02
- 天演药业将出席SVB Leerink第十一届全球医疗健康会议22-02-08
- Morgan Stanley Maintains Overweight on Adagene, Lowers Price Target to $1522-02-01
- 天演药业宣布已完成其独特原创的抗CD137与抗 CTLA-4联合疗法的全球首例患者给药22-01-28
- Adagene Announces First Patient Dosed With Novel, Proprietary Combination Of Ant...22-01-27
- NASDAQ TRADE HALT ADAG.O VOLATILITY TRADING PAUSE AT 09:31 AM22-01-25
- Stocks That Hit 52-Week Lows On Tuesday22-01-25
- Morgan Stanley Maintains Overweight on Adagene, Lowers Price Target to $2722-01-06
- 天演药业(ADAG.US)与Exelixis掩蔽型安全抗体偶联药物合作项目取得里程碑进展21-12-24
- The Daily Biotech Pulse: Novartis Snags Twin FDA Nods, Novavax Positive Vaccine ...21-12-23
- BRIEF-Adagene Achieves Key Milestone In Collaboration With Exelixis For SAFEbody...21-12-23
- 天演药业(ADAG.US)最新数据展示ADG153及ADG152临床前差异化优势21-12-14
- 12 Health Care Stocks Moving In Tuesday's Intraday Session21-12-14
- 天演药业(ADAG.US)：抗CTLA-4单抗ADG116在冷肿瘤(含胰腺癌和卵巢癌)中观察到良好的安全...21-12-07
- Adagene's Posts Early Safety, Efficacy Data From Cold Tumors Trial21-12-07
- Adagene Presents Clinical Data Co Says Demonstrates Strong Safety, Early Signals...21-12-06
- 天演药业(ADAG.US)宣布FDA已批准其抗CTLA-4抗体ADG116与抗PD-1帕博利珠单抗联合疗法Ib...21-11-30
- 20 Stocks Moving In Tuesday's Pre-Market Session21-11-30
- Adagene Shares Jump After FDA Signs Off ADG116/Keytruda Combo Therapy Trial In S...21-11-30
- 12 Health Care Stocks Moving In Monday's After-Market Session21-11-29
- 天演药业(ADAG.US)在新加坡启动ADG106联合纳武单抗治疗非小细胞肺癌患者的临床试验合作21-10-27
- NASDAQ TRADE HALT ADAG.O VOLATILITY TRADING PAUSE AT 09:35 AM21-09-01
- 天演药业(ADAG.US)H1净收入136万美元，归母净亏损扩大至3719万美元21-08-26
- BRIEF-Adagene Inc - Cash And Cash Equivalents Were US$208.3 Mln As Of June 30, 2...21-08-26
- 天演(ADAG.US)宣布与默沙东(MRK.US)开展第三项临床试验合作21-08-19
- Adagene Inks Third Cancer Trial Collaboration With Merck21-08-19
- 天演药业宣布任命代理首席医学官以及科学与战略顾问委员会新成员21-08-12
- 62 Biggest Movers From Yesterday21-07-28
- 快讯 | 天演药业与默沙东达成合作，改良CTLA-4抗体联合Keytruda进行临床试验21-07-23
- 默沙东(MRK.US)联手天演药业(ADAG.US)展开临床试验合作21-07-22
- Adagene To Test Its Anti-CTLA-4 Monoclonal Antibodies In Combination With Keytru...21-07-22
- 天演药业拟回购至多2000万美元股票，股价收涨超6%21-07-08
- 美股异动 | 天演药业(ADAG.US)盘初涨近5%，宣布至多2000万美元股票回购计划21-07-07
上一页下一页